focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Lol i didnt say it was sng, learn to read before commenting.. i said that those results show just how important sng is!
Again just shows how important sng is..
Roche “In a separate study, the healthcare firm found its drugs reduce the likelihood that patients with coronavirus-related pneumonia require ventilation.
Patients taking one of its drugs were 44% less likely to need ventilators or succumb to death, Roche said, citing a study conducted in countries including the US, South Africa, Brazil, and Mexico.
"The EMPACTA trial demonstrated that Actemra/RoActemra can reduce the need for mechanical ventilation in patients with COVID-19 associated pneumonia, an important outcome in this serious disease," Levi Garraway, Roche's chief medical officer, said in a statement.”
https://markets.businessinsider.com/news/stocks/stock-price-roche-unveils-covid19-antibody-test-ventilators-1029601942
Trek
Due for next RNS update....
Great post, Tornadotony. Thank you for it.
The big problem with IV interferon beta-1a has been the adverse effects and a large part in why it didn't live up to it's hype in the 70s and 80s. I agree that is what makes inhaled SNG001 so groundbreaking. It doesn't seem to have anywhere near the same adverse effects and targets the exact same pathway as the virus. I think people are starting to realise just how amazing that is. In all my research into interferons, beta-1a seems to be the most efficient at targeting this virus and for use in several other autoimmune diseases. Add to that the lack of adverse effects seen with SNG001 compared to IV interferon beta-1a together with the unique patented delivery system and you have something truly incredible.
If you look at the combined sales of Rebif and Avonex, two leading IV interferon beta-1a medications, in 2013 with a total of 5.51 billion dollars in revenue you can start to imagine the market value for an inhaled version with far fewer adverse side effects.
The more I look into this the more sure I am about the efficiency and safety of SNG001 in combating this virus, future viruses, and a host of other illnesses.
hold4 results
The tornado reference is that I was brought up as a kid in the tornado valley where they travel northeast from Nebraska which ends in Chicago on lake Michigan (hence its name as the windy city).
Tony
I wish to apologise for once calling you Windy Tony. You are clearly a force of nature.
We shall fight on the beaches.
Though I feel I must point out we are not against the odds here - the odds are very much on our side.
We have not forgotten how to love
1. Out of all the interferons there are two showing efficacy against Covid -19 as it was believed as of April this year they were Interferon Beta-1a (Synairgen ) and alfa-2b which I think the Canadian researchers are working on. The Canadians are 3 months behind Synairgen and are yet to publish stage 2 results as far as I am aware. I am stilling looking at other interferons but of course they act on different parts of the immune system.
2. Injecting interferon Beta-1A into the blood stream has a history of adverse drug reactions. Hence why USA stayed clear of what Synairgen have done thus far. This product is a nebulised air delivery route and the observations noted in July were very different to what many may have expected. (Ignore any intravenous applications as they are not relevant as a competitive therapy solution.)
3. Interferon 1 family activates RNA protein kinase and Covid-19 is a single stranded RNA virus and so it is likely that it may have some impact on the replication rate of the virus in the lung.
The novelty is having a different delivery route to an organ desperately affected by Covid-19. It is also choosing an interferon that many would have avoided because of the previous history of adverse drug reactions in the intravenous route. Overall I can understand caution being taken, but I would certainly run a phased operation from a pilot run of supply and carefully watch over the process.
I do feel the Battle of Britain of moment is right now on Covid-19 in Whitehall. Quite often serendipity and chance deliver an unexpected solution and incredibly its potentially the Synairgen product against all the odds.. I just hope someone is brave enough to make the final decision to make this product available and if they need a cautious entry route apply it.
Its like someone discovers they have early cancer at stage 1A and they do not believe it as they have minimal adverse symptoms. Its only family members and the clinician who can convince them just how lucky they are to have the choice of an alternative healthcare pathway. It is just possible that Synairgen interferon therapy and route of treatment is that most desirably alternative pathway with respect to reducing mortality from Covid-19 and down grading the threat from this virus.